Chemotherapy Delays Due to SARS-COV-2 in Children With Leukemia or Lymphoma

Jenny Ruiz,Zachary Aldewereld,Caitlin Elgarten

DOI: https://doi.org/10.1001/jamanetworkopen.2023.55679

2024-02-17

JAMA Network Open

Abstract:Studies, although limited, have shown conflicting findings in the clinical presentation and outcomes of COVID-19 in children with cancer. 1 Hashmi et al 2 focused on pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) and the acute clinical presentation of COVID-19 in children (aged 1-18 years) treated at St Jude Children's Research Hospital and its affiliate sites between March 2020 and June 2022. In this retrospective cohort study, 2 the authors reviewed COVID-19 symptoms, adverse events, chemotherapy administration, and COVID-19 reinfections during the 60-day follow-up period from time of COVID-19 diagnosis. Hashmi et al 2 found that 110 of 308 patients (36%) with ALL or LLy who were treated during this time had a SARS-CoV-2 infection. These patients were older compared with patients with ALL or LLy without COVID-19 and were more likely to be of Hispanic or an unspecified ethnicity. Seven patients (6%) met criteria for severe COVID-19, which was defined as symptoms of chest pain, shortness of breath, tachypnea, increasing oxygen requirement, lobar pneumonia on imaging, or admission to an intensive care unit. 2 Severe illness was associated with older age and lower absolute lymphocyte count at the time of COVID-19 diagnosis. In this cohort, chemotherapy was delayed for 96 patients (87%) for a median (IQR) of 8 (7-14) days following a SARS-CoV-2 infection. 2 The authors noted that chemotherapy delays were shorter in the post-Omicron period compared with the pre-Omicron period. Eleven patients (10%) had a SARS-CoV-2 reinfection. 2 They concluded that a higher incidence of SARS-CoV-2 infection was seen in this cohort of patients with ALL and LLy compared with the general pediatric population and recommended monitoring of patients at risk for severe COVID-19. Despite the low rate of severe disease in this study, 2 chemotherapy was temporarily delayed in the majority of patients who received a diagnosis of SARS-CoV-2 infection. Given the low rates of severe disease in this cohort and others, this practice should be reconsidered in favor of guidance to prioritize treatment of the underlying leukemia, even after documented SARS-CoV-2 positivity. 3 The authors 2 raise the possibility that these delays in care could lead to a survival disadvantage. Reassuringly, although frequent and prolonged treatment interruptions do have the potential to impact survival outcomes of ALL, short interruptions for a variety of indications beyond COVID-19 are quite common and do not impact relapse-free or overall survival. 4 Furthermore, because there was a reduction in the incidence of non–SARS-CoV-2 respiratory infections during this period due to COVID-19 directed-interventions, 5 children may have experienced fewer net delays in chemotherapy delivery. Further supporting the notion that treatment delays may be minimized was the substantial reduction in disease severity observed in the post-Omicron period. 2 Notably, only 1 severe case was seen in the study during this period. 2 This experience mirrors that seen in immunocompetent patients, for whom considerably decreased disease severity has been observed. 6 Coupled with the availability of antiviral agents in the form of remdesivir (and for patients 12 years and older, nirmatrelvir), the opportunity appears to exist to avoid prolonged delays in chemotherapy, particularly in children without other risk factors for severe disease. Interestingly, the vast majority of patients in this study 2 did not receive COVID-19 directed antiviral therapy, but use of these agents may have been able to shorten treatment delays. Similar to other pediatric cancer studies, 1 Hashmi et al 2 found a higher risk for SARS-CoV-2 infection in Hispanic children with ALL and LLy compared with non-Hispanic children. Additionally, although not statistically significant, the point estimate of patients who had SARS-CoV-2 infection was higher in Black children compared with White children or children of other races and ethnicities (defined as American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, and unspecified). 2 Much has been written about the disproportionate impact of COVID-19 on racial and ethnic minority groups and how social determinants of health (SDOH)—like gaps in wealth, housing, and employment—contributed to this disparity. 7 St Jude Children's Research Hospital is known for covering the cost of treatment, travel, housing, and food for all their patients, 8 which in theory may help mitigate adverse SDOH. However, the higher risk for SARS-CoV-2 infection in Hispanic children in this cohort 2 suggests an unmeasured influence of SDOH. Applying an SDOH lens on pediatric oncology ou -Abstract Truncated-

medicine, general & internal